There are 2789 resources available
Discussion 515MO and 516MO
Presenter: Aung Naing
Session: Mini oral session - Developmental therapeutics
Resources:
Slides
Webcast
Discussion 517MO and 518MO
Presenter: Richard Schlenk
Session: Mini oral session - Developmental therapeutics
Resources:
Slides
Webcast
Discussion 519MO and 520MO
Presenter: Richard Baird
Session: Mini oral session - Developmental therapeutics
Resources:
Slides
Webcast
LBA14 - Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study
Presenter: Sara Hurvitz
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
121MO - Acute toxicity associated with a 3-week versus a standard 5-week regimen for locoregional breast radiotherapy delivered in the UNICANCER HypoG-01 phase III trial
Presenter: Sofia Rivera
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
122MO - Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib
Presenter: José García-Saenz
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
123MO - BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer
Presenter: Peter Schmid
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
1038MO - Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial
Presenter: Ivan Marquez-Rodas
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1039MO - CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM)
Presenter: Kim Margolin
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA39 - Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study
Presenter: Christian Blank
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast